Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury

Toll-like receptor 4 (TLR4) signaling plays a key role in liver inflammation and fibrosis. The therapeutic effects of eritoran, a TLR4 antagonist, in mice with chronic liver injury remained unclear. C57BL/6 mice were fed a fast-food diet (FFD) or treated with carbon tetrachloride (CCl4) to induce chronic liver injury. Eritoran (10 mg/kg) or a vehicle was randomly intraperitoneally administered to the FFD-fed mice and the CCl4-injured mice. Primary mouse liver cells were cultured with lipopolysaccharide (LPS) or eritoran. In both FFD and CCl4 mouse models, eritoran significantly reduced serum ALT levels and decreased hepatic inflammatory cell infiltration without altering hepatic steatosis. Additionally, eritoran attenuated liver fibrosis by decreasing hepatic stellate cells (HSCs) activation and the abundance of α-smooth muscle actin and transforming growth factor-β1. Hepatic TLR4 downstream signaling including MyD88 expression, NF-κB p65 nuclear translocation, p38 and JNK phosphorylation were successfully inhibited by eritoran. In the in vitro study, LPS-induced nuclear translocation of NF-κB in primary HSCs and Kupffer cells was significantly suppressed by eritoran. In conclusion, eritoran attenuated hepatic inflammation and fibrosis by inhibition of the TLR4 signaling pathway in mice with chronic liver injury. Eritoran may serve as a potential drug for chronic liver disease.

[1]  H. Loeffler-Wirth,et al.  Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. , 2020, Journal of hepatology.

[2]  S. Friedman,et al.  New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. , 2019, Current opinion in pharmacology.

[3]  Han‐Chieh Lin,et al.  Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease , 2019, Laboratory Investigation.

[4]  L. Vonghia,et al.  Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease , 2019, Frontiers in Immunology.

[5]  Hongliang Li,et al.  Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease , 2018, Trends in Endocrinology & Metabolism.

[6]  K. Zengler,et al.  The Role of Intestinal C‐type Regenerating Islet Derived‐3 Lectins for Nonalcoholic Steatohepatitis , 2018, Hepatology communications.

[7]  Yong-soo Lee,et al.  Hepatocyte toll-like receptor 4 mediates lipopolysaccharide-induced hepcidin expression , 2017, Experimental & Molecular Medicine.

[8]  Hongliang Li,et al.  Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4 , 2017, Nature Medicine.

[9]  Ş. Kızıltaş Toll-like receptors in pathophysiology of liver diseases , 2016, World journal of hepatology.

[10]  Han‐Chieh Lin,et al.  Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice , 2016, Scientific Reports.

[11]  J. Antoun,et al.  Hepatic TLR4 signaling in obese NAFLD. , 2015, American journal of physiology. Gastrointestinal and liver physiology.

[12]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[13]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[14]  R. Schwabe,et al.  High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers , 2015, Nature Protocols.

[15]  Yuanqing Liu,et al.  A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal Species , 2014, Front. Immunol..

[16]  J. Elmquist,et al.  Hepatocyte Toll-like Receptor 4 Regulates Obesity-Induced Inflammation and Insulin Resistance , 2014, Nature Communications.

[17]  J. Odin,et al.  Toll‐like receptors and liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[18]  T. Billiar,et al.  Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma. , 2013, The Journal of surgical research.

[19]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[20]  Derrick E Fouts,et al.  Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. , 2012, Journal of hepatology.

[21]  K. Iwaisako,et al.  Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist , 2012, Proceedings of the National Academy of Sciences.

[22]  Gang Wang,et al.  A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development , 2012, Cytotechnology.

[23]  P. Knuefermann,et al.  In Vivo Toll-Like Receptor 4 Antagonism Restores Cardiac Function During Endotoxemia , 2011, Shock.

[24]  G. Gores,et al.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[25]  A. Dolganiuc,et al.  Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[26]  D. Brenner,et al.  Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease , 2011, Gastroenterology research and practice.

[27]  S. Friedman,et al.  Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis , 2010, Fibrogenesis & tissue repair.

[28]  T. Tsujimoto,et al.  Salvage effect of E5564, Toll‐like receptor 4 antagonist on d‐galactosamine and lipopolysaccharide‐induced acute liver failure in rats , 2010, Journal of gastroenterology and hepatology.

[29]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[30]  G. Gerken,et al.  Toll‐like receptor‐induced innate immune responses in non‐parenchymal liver cells are cell type‐specific , 2010, Immunology.

[31]  T. F. Murray,et al.  Effects of the second-generation synthetic lipid A analogue E5564 on responses to endotoxin in [corrected] equine whole blood and monocytes. , 2008, American journal of veterinary research.

[32]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[33]  P. Adegboyega,et al.  Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. , 2007, Journal of hepatology.

[34]  Hayyoung Lee,et al.  Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran , 2007, Cell.

[35]  J. Carvalheira,et al.  Loss-of-Function Mutation in Toll-Like Receptor 4 Prevents Diet-Induced Obesity and Insulin Resistance , 2007, Diabetes.

[36]  A. Simm,et al.  E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes , 2006, Inflammation Research.

[37]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[38]  Christian Jobin,et al.  Toll‐Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells , 2003, Hepatology.

[39]  F. Gusovsky,et al.  Inhibition of Endotoxin Response by E5564, a Novel Toll-Like Receptor 4-Directed Endotoxin Antagonist , 2003, Journal of Pharmacology and Experimental Therapeutics.

[40]  D. Rossignol,et al.  Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue , 2002, Journal of endotoxin research.

[41]  Hongliang Li,et al.  Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. , 2019, Physiological reviews.

[42]  T. Billiar,et al.  Toll-like Receptor 4 (TLR4) Antagonist Eritoran Tetrasodium Attenuates Liver Ischemia and Reperfusion Injury through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling , 2015, Molecular medicine.

[43]  R. Schwabe,et al.  TLR4 enhances TGF-beta signaling and hepatic fibrosis. , 2007, Nature medicine.

[44]  S. Friedman,et al.  Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.

[45]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.